0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Editorial |

AIDS and Ophthalmology, 2008

Douglas A. Jabs, MD, MBA
Arch Ophthalmol. 2008;126(8):1143-1146. doi:10.1001/archopht.126.8.1143.
Text Size: A A A
Published online

Extract

In 1981, a new disease, characterized by opportunistic infections (OIs) and unusual neoplasms, was reported to the Centers for Disease Control and Prevention.1 This disease, AIDS, was soon thereafter discovered to be caused by the human immunodeficiency virus (HIV), which invades cells of the immune system, particularly CD4+ T cells, resulting in their loss and the subsequent immune deficiency. From the beginning, it was evident that the eye was a frequent target organ in AIDS.2 The most frequent ocular manifestation was HIV retinopathy, consisting of cotton-wool spots with or without intraretinal hemorrhages.2,3 Histologic and fluorescein angiographic studies also demonstrated the presence of other vascular abnormalities, including microaneurysms and telangiectatic vessels.35 The most devastating ocular complications were ocular OIs, particularly cytomegalovirus (CMV) retinitis. Cytomegalovirus retinitis affected an estimated 30% of patients with AIDS sometime during the course of AIDS,6 and the rate among patients with CD4+ T-cell counts lower than 50 cells/μL was 0.20 cases/person-year (PY).7 By the early 1990s, CMV retinitis became the most common intraocular infection seen by ophthalmologists at major urban centers.8 Drugs to treat CMV retinitis were introduced in the late 1980s, including ganciclovir sodium (Cytovene; Roche Pharmaceuticals, Nutley, New Jersey; approved in 1989) and foscarnet sodium (Foscavir; AstraZeneca LP, Wilmington, Delaware; approved in 1991), and later, cidofovir (Vistide; Gilead Sciences, Inc, Foster City, California; approved in 1996) and fomivirsen sodium (Vitravene; Novartis Ophthalmics AG, Bulach, Switzerland, and Isis Pharmaceuticals, Inc, Carlsbad, California; approved in 1998). Treatment was initially given intravenously at higher doses for 2 to 3 weeks (induction therapy), followed by lifetime therapy at lower doses to prevent relapse of the disease (maintenance therapy or secondary prophylaxis). An oral form of ganciclovir with poor bioavailability was introduced and then replaced by valganciclovir hydrochloride (Valcyte; Roche Pharmaceuticals; approved in 2001), which had a good bioavailability after oral administration and produced ganciclovir blood levels similar to those of intravenous ganciclovir.9 Intravitreal injections of ganciclovir and foscarnet also were used to deliver higher drug concentrations to the retina and avoid systemic adverse effects. To improve local delivery of ganciclovir, a sustained-released implant (Vitrasert; Bausch & Lomb, Inc, San Dimas, California; approved 1996), which lasts approximately 6 months, was developed and Food and Drug Administration approved in 1996.10 However, because CMV is a systemic infection, local delivery of anti-CMV agents was associated with high rates of contralateral ocular and visceral disease and with an increased mortality.3,1113 Because of the disadvantages of local therapy, the implant typically was combined first with oral ganciclovir14 and now with valganciclovir.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 11

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
Jobs
JAMAevidence.com
brightcove.createExperiences();